Xeltis: Transforming clinical trial oversight with real-life evidence

The Challenge

Xeltis develops cardiovascular devices that use endogenous tissue restoration — a technology built on Nobel Prize-winning chemistry that enables the body to grow its own replacement tissue. With breakthrough clinical trials underway across the United States, their devices were being implanted in patients at 28 geographically dispersed sites.

The clinical team faced a critical oversight gap. Patients with cannulation sites needed careful post-operative monitoring, but traditional clinic appointments only provided sporadic snapshots. Between visits, life-threatening issues like pseudo-aneurysms could develop and escalate before anyone on the clinical team had any visibility.

The surgeons had no way to observe healing progress in real time, and no way to maintain consistent oversight across all 28 trial locations.

For a device built on the principle that the body heals itself, the inability to actually watch that healing process unfold was a significant blind spot.

‍

The Approach

Xeltis partnered with Indeemo to replace sporadic clinic visits with a continuous visual audit trail. The approach was straightforward: put patients in control of capturing their own healing evidence, and give the clinical team remote, real-time visibility across every trial site.

Weekly patient check-ins — each patient captured and uploaded visual evidence of their cannulation sites via the Indeemo app on their own phone. This created 52 structured touchpoints per year compared to the handful of in-clinic appointments they would otherwise have had.

Scheduled tasking — Indeemo's scheduling capability meant patients received prompts at consistent intervals. The clinical team didn't have to chase submissions — the platform handled the cadence.

Patient empowerment — rather than being passive subjects waiting for their next appointment, patients became active participants in monitoring their own site rotation. This increased engagement and gave patients ownership of their care.

Consistent visibility across sites — regardless of which of the 28 US trial locations a patient attended, the clinical team at Xeltis had the same level of visual oversight. No site was a blind spot.

‍

The Results

The impact was immediate and measurable. With weekly visual check-ins replacing sporadic clinic visits, the Xeltis clinical team could identify emerging issues early — before they escalated to septic events. Pseudo-aneurysms that would previously have gone undetected between appointments were now caught in their earliest stages.

Across all 28 US trial sites, the result was zero missed critical events. Every patient was monitored with the same rigour, regardless of their geographic location or which clinical site they attended.

The approach also fundamentally changed the patient-clinician relationship. Patients reported feeling more in control of their own care, and the clinical team gained a level of longitudinal insight that traditional trial monitoring simply could not provide — a multi-year visual audit trail of real-world healing evidence, built one weekly check-in at a time.

With the platform's support for 34 languages, Xeltis is now positioned to scale this approach internationally as their trials expand beyond the US market into Europe and Asia.